Please login to the form below

Not currently logged in


This page shows the latest Evrysdi news and features for those working in and with pharma, biotech and healthcare.

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

Another competitor in the SMA market – Roche’s Evrysdi (risdiplam) – was recently approved in the US for the treatment of SMA in adults and children aged two months and older, following ... Roche has priced Evrysdi by patient weight, with a maximum

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...